Verrica Pharmaceuticals stockholders approve equity plan and re-elect two directors
At its June 5, 2026 annual meeting, Verrica Pharmaceuticals stockholders approved the Amended and Restated 2018 Equity Incentive Plan, which took effect immediately, and re-elected two directors. The filing shows all proposals passed, with shareholder votes on the equity plan and executive pay drawing more opposition than the other items.
Key points
- Stockholders approved the Amended and Restated 2018 Equity Incentive Plan, with 11,142,881 votes for and 433,852 against
- Paul B. Manning and Lawrence Eichenfield were elected as directors to serve until the 2029 annual meeting
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for fiscal 2026 with 14,058,234 votes for
- 14,069,331 shares, or 81.89% of the 17,178,786 shares outstanding on the record date, were present or represented at the meeting
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.